Literature DB >> 22136737

Contribution of anti-ryanodine receptor antibody to impairment of excitation-contraction coupling in myasthenia gravis.

Tomihiro Imai1, Emiko Tsuda, Takayoshi Hozuki, Hiroaki Yoshikawa, Rika Yamauchi, Masaki Saitoh, Shin Hisahara, Masakatsu Motomura, Jun Kawamata, Shun Shimohama.   

Abstract

OBJECTIVE: The aim of this study was to elucidate the relationship between the impairment of excitation-contraction (E-C) coupling and anti-ryanodine receptor (RyR) antibody in patients with myasthenia gravis (MG).
METHODS: Masseteric compound muscle action potential (CMAP) and mandibular movement-related potentials (MRPs) were recorded simultaneously after stimulating the trigeminal motor nerve with a needle electrode. The E-C coupling time (ECCT) was calculated as the latency difference between CMAP and MRP. For each patient, we selected a representative data set when there was no abnormal decrement in response to repetitive nerve stimulation. The 26 data sets were divided into an anti-RyR-positive group (n=12) and an anti-RyR-negative group (n=14).
RESULTS: Masseteric ECCT was significantly longer (p=0.017) in anti-RyR-positive group (median, mean, range; 3.6, 3.8, 3.0-5.9 ms) than in anti-RyR-negative group (3.1, 3.1, 2.7-4.0) although there were no significant differences in masseteric CMAP amplitude and % decrement between the two groups. The bite force was significantly lower in anti-RyR-positive group than in normal controls.
CONCLUSIONS: Presence of anti-RyR antibodies is associated with significantly prolonged masseteric ECCT compared to absence of the antibodies in MG. SIGNIFICANCE: Anti-RyR antibody contributes to E-C coupling impairment in the masseter muscle in patients with MG.
Copyright © 2011 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22136737     DOI: 10.1016/j.clinph.2011.10.038

Source DB:  PubMed          Journal:  Clin Neurophysiol        ISSN: 1388-2457            Impact factor:   3.708


  3 in total

Review 1.  Ryanodine receptor patents.

Authors:  Alexander Kushnir; Andrew R Marks
Journal:  Recent Pat Biotechnol       Date:  2012-12

2.  Differential RNA Expression Profile of Skeletal Muscle Induced by Experimental Autoimmune Myasthenia Gravis in Rats.

Authors:  Henry J Kaminski; Keiichi Himuro; Jumana Alshaikh; Bendi Gong; Georgiana Cheng; Linda L Kusner
Journal:  Front Physiol       Date:  2016-11-10       Impact factor: 4.566

3.  Cytometric cell-based assays for anti-striational antibodies in myasthenia gravis with myositis and/or myocarditis.

Authors:  Kenji Kufukihara; Yurika Watanabe; Takashi Inagaki; Koutaro Takamatsu; Shunya Nakane; Jin Nakahara; Yukio Ando; Shigeaki Suzuki
Journal:  Sci Rep       Date:  2019-03-27       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.